

**FINANCIAL SUPERVISORY AUTHORITY**

Piękna 20  
00-549 Warsaw  
P.O. Box 419

and

**Captor Therapeutics S.A.**

Duńska 11  
54-427 Wrocław

(the "**Company**")

I, Sylvain Cottens, pursuant to Article 69.1.2) and 69.2.1) of the Act on Public Offering<sup>1</sup>, hereby notify of a decrease in my shareholding in the Company to 9.98% of the total number of votes as a result of the registration on 24 May 2021 by the District Court for Wrocław-Fabryczna in Wrocław, 6th Commercial Division of the National Court Register, of an increase in the Company's share capital from PLN 325,647.20 to PLN 412,797.20 through the issuance of 871,500 series G ordinary shares (the "**Increase**").

1. Prior to the Increase, I held 340,897 shares in the Company, representing 10.47% of all shares in the Company and in the Company's share capital, and carrying 526,730 votes in the Company, representing 11.96% of all votes in the Company, including
  - a) 152,500 series A preferred shares (one share carries 2 votes in the Company), representing 4.68% of all shares in the Company and in the Company's share capital, and entitling to 305,000 votes in the Company, representing 6.93% of all votes in the Company,
  - b) 152,500 ordinary shares of series B, representing 4.68% of all shares in the Company and in its share capital, and entitling to 152,500 votes in the Company, representing 3.46% of all votes in the Company,
  - c) 33,333 series E preferred shares (one share carries 2 votes in the Company), representing 1.02% of all shares in the Company and in the Company's share capital, and carrying 66,666 votes in the Company, representing 1.51% of all votes in the Company;
  - d) 2,564 ordinary shares of series F, representing 0.08% of all shares in the Company and in its share capital, and carrying 2,564 votes in the Company, representing 0.06% of all votes in the Company.
2. As a result of the Increase, I hold 340,897 shares in the Company, representing 8.26% of all shares in the Company and in the share capital of the Company, and carrying 526,730 votes in the Company, representing 9.98% of all votes in the Company, including:
  - a) 152,500 series A preferred shares (one share carries 2 votes in the Company), representing 3.69% of all shares in the Company and in the Company's share capital, and entitling to 305,000 votes in the Company, representing 5.78% of all votes in the Company,

---

<sup>1</sup> Act of 29 July 2005 on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organised Trading, and Public Companies ("**the Act on Public Offering** ")

- b) 152,500 ordinary shares of series B, representing 3.69% of all shares in the Company and in its share capital, and entitling to 152,500 votes in the Company, representing 2.89% of all votes in the Company,
  - c) 33,333 series E preferred shares (one share carries 2 votes) representing 0.81% of all shares in the Company and in the Company's share capital, and carrying 66,666 votes in the Company, representing 1.26% of all votes in the Company;
  - d) 2,564 ordinary shares of series F, representing 0.06% of all shares in the Company and in its share capital, and carrying 2,564 votes in the Company, representing 0.05% of all votes in the Company.
3. There are no subsidiaries belonging to me that hold shares in the Company. With respect to me there are no persons referred to in Article 87 section 1 item 3 letter c of the Act on Public Offering.
4. I do not own financial instruments which, upon maturity, unconditionally entitle or oblige their holder to purchase shares of the Company, with which voting rights are related, already issued by the Company, or which relate to shares of the Company in a direct or indirect manner and have economic effects similar to the effects of financial instruments defined in the previous sentence, regardless of whether these instruments are executed through cash settlement, and referred to in art. 69b par. 1.1) and 69b par. 1.2) of the Act on Public Offering. According to the above, I do not have votes from shares indicated on the basis of art. 69 par. 4 point 7) and 8) of the Act on Public Offering.

**On behalf of Sylvain Cottens:**



Wojciech Grabowski

attorney-in-fact

May 27, 2021

**POWER OF ATTORNEY**

I, the undersigned, **Sylvain Cottens** ("**Principal**") hereby grant power of attorney to:

**Maciej Wróblewski**

and

**Wojciech Grabowski**

(hereinafter referred to collectively as the "**Attorney(s)**" and individually as the "**Attorney**")

each individually to:

1. to make any representations under or in connection with the Act of 29 July 2005 on Public Offering and Conditions Governing the Introduction of Financial Instruments to Organised Trading and Public Companies to the Polish Financial Supervisory Authority (*Komisja Nadzoru Finansowego*) and Captor Therapeutics S.A. with its registered seat in Wrocław (the "**Company**") in relation to any shares in the Company;
2. to sign and file all documents, letters, annexes and forms as may be necessary or appropriate to exercise the foregoing powers and to make all declarations of will and knowledge on behalf of the Principal and to perform all legal acts and take all other actions deemed necessary or appropriate to exercise the foregoing powers; and
3. to conduct and receive all correspondence addressed to the Principal in the above respect.

The Attorney is authorized to grant further power of attorney.

This power of attorney is valid until revoked.



**Sylvain Cottens**